Caplacizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Caplacizumab
Monoclonal antibody
Type Single domain antibody
Source Humanized
Target VWF
Clinical data
Synonyms ALX-0081
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C1213H1891N357O380S10
Molar mass 27.88 kg/mol

Caplacizumab (ALX-0081) (INN) is a bivalent VHH designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[1][2]

This drug was developed by Ablynx NV.[3] On 31 August 2018 it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression".[4]

It is an anti-von Willebrand factor humanized immunoglobulin.[5] It acts by blocking platelet aggregation to reduce organ injury due to ischemia.[5] Results of the phase II TITAN trial have been reported.[5]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.
  2. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
  3. ^ A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)
  4. ^ European Medicines Agency. "An overview of Cablivi and why it is authorised in the EU" (PDF). Retrieved 1 October 2018.
  5. ^ a b c Immune Drug Tackles Microvascular Thrombosis Disorder. Feb 2016